TransCode Therapeutics, Inc., (RNAZ): Price and Financial Metrics
GET POWR RATINGS... FREE!
RNAZ Stock Price Chart Interactive Chart >
RNAZ Price/Volume Stats
| Current price | $0.75 | 52-week high | $3.08 |
| Prev. close | $0.91 | 52-week low | $0.28 |
| Day low | $0.71 | Volume | 5,984,903 |
| Day high | $0.94 | Avg. volume | 724,610 |
| 50-day MA | $0.56 | Dividend yield | N/A |
| 200-day MA | $1.24 | Market Cap | 9.74M |
TransCode Therapeutics, Inc., (RNAZ) Company Bio
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Latest RNAZ News From Around the Web
Below are the latest news stories about TRANSCODE THERAPEUTICS INC that investors may wish to consider to help them evaluate RNAZ as an investment opportunity.
How should investors view TransCode Therapeutics Inc. Common Stock (RNAZ)?TransCode Therapeutics Inc. Common Stock (NASDAQ:RNAZ) marked $0.67 per share on Friday, up from a previous closing price of $0.57. While TransCode Therapeutics Inc. Common Stock has overperformed by 18.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RNAZ fell by -72.30%, with highs and lows […] |
FDA Authorizes TransCode''s First-In-Human Clinical Trial With Solid Tumor PatientsTransCode Therapeutics Inc (NASDAQ: RNAZ ) has received written authorization from the FDA to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode''s lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors. TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, … Full story available on Benzinga.com |
TransCode Therapeutics Inc. (RNAZ) produces promising resultsAs of Wednesday, TransCode Therapeutics Inc.’s (NASDAQ:RNAZ) stock closed at $0.61, up from $0.40 the previous day. While TransCode Therapeutics Inc. has overperformed by 51.82%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, RNAZ fell by -75.60%, with highs and lows ranging from $3.13 to $0.28, […] |
TransCode stock surges ~25% on FDA nod to start phase 0 trial of cancer drugTransCode Therapeutics (RNAZ) said it received authorization from the U.S |
FDA Authorizes TransCode's First-In-Human Clinical Trial With Solid Tumor PatientsTransCode Therapeutics Inc (NASDAQ: RNAZ) has received written authorization from the FDA to proceed with its First-in-Human (FIH) Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors. TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in several advanced solid tumors. Related: TransCode Therapeutics Shares Sho |
RNAZ Price Returns
| 1-mo | 11.44% |
| 3-mo | 24.98% |
| 6-mo | -43.18% |
| 1-year | -67.39% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 11.44% |
| 2022 | -73.50% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...